| HOME >> BIOLOGY >> TECHNOLOGY |
Some matters discussed in this press release constitute
"forward-looking statements" that involve known and unknown risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by the forward-looking statements. Such
forward-looking statements include statements about the patch vaccine being
a prophylaxis for travelers' diarrhea, the timing for commencing Phase 3
studies, the potential size of the market for a travelers' diarrhea
vaccine; the applicability of TCI technology to other pathogens; and that,
if approved, Iomai's vaccine would be the first available in the U.S.
Applicable risks and uncertainties include, among others, that Iomai may
not be able to enroll sufficient numbers of patients in future clinical
trials; that future clinical trials may not replicate results seen in the
trial described in this press release; that Iomai may be unable to obtain
the regulatory approvals necessary to conduct additional clinical trials or
to market any product for travelers' diarrhea; that estimates of market
size overstate the number of travelers who would use such a product, if it
were approved; that competitors may develop products that are safer, more
effective, or more convenient to use; and the risks identified under the
heading "Factors That May Impact Future Results" in Management's Discussion
and Analysis of Financial Condition and Results of Operations in Iomai's
Quarterly Report on Form 10-Q for the three months ended June 30, 2007, and
filed with the Securities and Exchange Commission. While Iomai believes
that this product candidate is amenable to self-administration, in the
Phase 2 study described in this press release, medical professionals
administered the vaccine. Whether any approved product would be
self-administered would depend on many factors, including the outcome of
any studies the Company conducts evaluating self-administration and the
views of regulatory agencies. Iom
'/>"/>
| SOURCE Iomai Corporation Copyright©2007 PR Newswire. All rights reserved |